Erdafitinib received accelerated approval from the US Food and Drug Administration in April 2019 after a phase 2 trial for locally advanced or metastatic urothelial carcinoma.1 It works as a tyrosine kinase inhibitor of fibroblast growth factor receptors (FGFRs) 1 to 4 (pan-FGFR inhibitor) and is the first FGFR kinase inhibitor approved by the US Food and Drug Administration.1 Retinal findings were noted in the phase 2 trial.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Parikh D, Eliott D, Kim LA. Fibroblast Growth Factor Receptor Inhibitor–Associated Retinopathy. JAMA Ophthalmol. 2020;138(10):1101–1103. doi:10.1001/jamaophthalmol.2020.2778
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: